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ABSTRACT
Background Pancreatic ductal adenocarcinoma (PDAC) 
is notoriously resistant to treatment including checkpoint- 
blockade immunotherapy. We hypothesized that a bimodal 
treatment approach consisting of dendritic cell (DC) 
vaccination to prime tumor- specific T cells, and a strategy 
to reprogram the desmoplastic tumor microenvironment 
(TME) would be needed to break tolerance to these 
pancreatic cancers. As a proof- of- concept, we investigated 
the efficacy of combined DC vaccination with CD40- 
agonistic antibodies in a poorly immunogenic murine 
model of PDAC. Based on the rationale that mesothelioma 
and pancreatic cancer share a number of tumor associated 
antigens, the DCs were loaded with either pancreatic or 
mesothelioma tumor lysates.
Methods Immune- competent mice with subcutaneously 
or orthotopically growing KrasG12D/+;Trp53R172H/+;Pdx-
1- Cre (KPC) PDAC tumors were vaccinated with syngeneic 
bone marrow- derived DCs loaded with either pancreatic 
cancer (KPC) or mesothelioma (AE17) lysate and 
consequently treated with FGK45 (CD40 agonist). Tumor 
progression was monitored and immune responses in TME 
and lymphoid organs were analyzed using multicolor flow 
cytometry and NanoString analyzes.
Results Mesothelioma- lysate loaded DCs generated 
cross- reactive tumor- antigen- specific T- cell responses to 
pancreatic cancer and induced delayed tumor outgrowth 
when provided as prophylactic vaccine. In established 
disease, combination with stimulating CD40 antibody was 
necessary to improve survival, while anti- CD40 alone 
was ineffective. Extensive analysis of the TME showed 
that anti- CD40 monotherapy did improve CD8 +T cell 
infiltration, but these essential effector cells displayed 
hallmarks of exhaustion, including PD-1, TIM-3 and 
NKG2A. Combination therapy induced a strong change 
in tumor transcriptome and mitigated the expression of 
inhibitory markers on CD8 +T cells.
Conclusion These results demonstrate the potency of 
DC therapy in combination with CD40- stimulation for the 
treatment of pancreatic cancer and provide directions for 
near future clinical trials.
INTRODUCTION
Pancreatic adenocarcinoma is currently the 
fourth- leading cause of cancer- related death 
in the USA and the third in Europe.1 2 The 
incidence is rising and it is expected that 
pancreatic cancer will be the second- leading 
cause of cancer- related death by 2030.3 The 
current prognosis of a newly diagnosed 
pancreatic cancer patient is poor with a 5- year 
survival of 8.5%.1 To date, surgical resec-
tion is the mainstay of curative treatment. 
However, this is usually not an option due to 
local vascular invasion or metastasis at diag-
nosis. Only 10%–20% of all pancreatic cancer 
patients are eligible for surgical resection and 
relapse rates are high.4 5 Adjuvant chemo-
therapy following surgical resection improves 
median overall survival, but even with new 
chemotherapy regimens cure is exceedingly 
rare.6 Therefore, new treatment modalities 
are desperately needed in order to achieve 
durable disease control in pancreatic cancer 
patients.
Although immunotherapy yields striking 
results in numerous malignancies, clinical 
responses in pancreatic cancer have been 
disappointing.7–9 Reasons for this poor 
clinical response are likely multifactorial. 
Pancreatic cancer has been considered an 
immunologically ‘cold’ tumor with rare 
infiltration of cytotoxic T cells, explaining 
the low response rates to immune check-
point antibodies.10–12 A highly immunosup-
pressive tumor microenvironment (TME) 
consisting of a plethora of cells including 
myeloid- derived suppressor cells (MDSCs), 
tumor associated macrophages (TAMs) and 
regulatory T cells (Tregs) in conjunction 
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with a characteristic dense desmoplastic stroma has been 
reported to be responsible for the observed T- cell exclu-
sion and dysfunction in established tumors.13 Several ther-
apeutic agents targeting the pancreatic TME have shown 
promising results.14 15 Seminal studies have investigated 
the potency of CD40- agonistic antibodies in modulating 
the TME and desmoplastic stroma of pancreatic cancers, 
thereby allowing T- cell infiltration and antitumor effi-
cacy.16 This was later shown to be dependent on strom-
alysis by TAM- precursors which, following upregulation 
of matrix metallo- proteases, degrade fibrosis and support 
the influx and antitumor efficacy of T cells.17 18 Although 
some clinical responses to CD40- agonistic antibodies 
have been reported, durable responses are limited. A lack 
of successfully presented and high- quality tumor anti-
gens has also been proposed to be involved in the lack 
of immune reactivity to pancreatic cancers.19 20 Akin to 
this, observational patient studies have shown rare long- 
term postresection pancreatic cancer survivors to have 
increased levels of tumor- reactive T cells in their periph-
eral blood and tumors.20 21 Dendritic cells (DCs) are the 
most potent T- cell activators of the immune system, and 
DC vaccination can successfully induce immune responses 
and clinical responses in various less- immunogenic malig-
nancies when loaded with the appropriate tumor anti-
gens.22 Ideally, these antigens should be derived from 
the patient’s own tumor. However, at this point in time, 
implementation of these personalized vaccines poses a 
logistical hurdle. An allogeneic ‘off- the- shelf’ strategy for 
tumor lysate could circumvent this issue and standardize 
treatment across patients. We have previously shown 
that treating mesothelioma patients with autologous 
DCs loaded with a allogeneic tumor lysate is feasible and 
induces immune responses and tumor regressions in a 
subset of patients.22 As several tumor- associated antigens 
(TAAs), such as cancer- testis antigens and tumor differen-
tiation antigens, are shared across different tumor types, 
this vaccine could be effective in other tumors as well, 
including pancreatic cancer, which coexpresses several 
TAAs with mesothelioma tumors (eg, mesothelin, WT-1, 
MUC1).
Here, we investigated the efficacy of DC vaccination 
in a representative murine model of human pancreatic 
ductal adenocarcinoma (PDAC). We show that vacci-
nation with mesothelioma lysate- loaded DCs yields 
tumor- specific immune responses against pancreatic 
cancer and decreases tumor progression. In estab-
lished tumors, significant prolonged survival was only 
achieved when DC vaccination was combined with 
an agonistic CD40 antibody. Extensive analysis of the 
TME showed that whereas CD40- agonistic antibodies as 
monotherapy improved intratumoral T- cell infiltration, 
these cells displayed hallmarks of exhaustion. In the 
combination treatment, an improved T- cell phenotype 
lacking the high expression of various inhibitory recep-
tors was observed. Therefore, CD40- agonistic antibody 
treatment may sensitize pancreatic tumors to tumor- 
specific immune responses induced by DC vaccination. 
These translational studies pave the way for future clin-
ical trials investigating DC vaccination in occult disease 
or as part of combination immunotherapy in inoper-
able pancreatic cancer patients, some of which have 
already been initiated (REACtiVe Trial).
RESULTS
DC vaccination with mesothelioma lysate induces T-cell 
immunity and efficacy against pancreatic cancer
We hypothesized that vaccination with DCs loaded 
with mesothelioma TAAs can generate a cross- reactive 
immune response against pancreatic cancer. We, there-
fore, evaluated whether pancreatic cancer (KPC3) lysate 
loaded- DCs or mesothelioma (AE17) lysate loaded- DCs 
induced protective immunity in mice challenged with 
KPC3 (figure 1A). Comparison of RNA- seq transcrip-
tome profiles of KPC3 and AE17, based on a predefined 
list of validated TAAs, revealed that 63% of the TAAs 
were expressed by both AE17 and KPC3 (figure 1B, 
online supplementary table S1).23 This supports the 
notion of shared antigens between the two cancer types. 
For a more unbiased approach, we also investigated the 
overlap in transcriptome profiles of KPC3, AE17 and 
two unrelated cell lines (B16F10, MC38) (online supple-
mentary figure S1). Shared transcripts could be found 
in all four tumor cell lines. Exposure of DCs to tumor 
lysates and CpG led to rapid upregulation of activation 
markers (eg, CD40, CD80/86) (online supplementary 
figure S2). Importantly, prophylactic vaccination of 
mice with DCs loaded with pancreatic or mesothelioma 
lysate was equally effective in delaying tumor growth and 
both had significant smaller tumor volumes compared 
with untreated mice at day 20 (figure 1C,D).
To elucidate the mechanisms underlying DC therapy 
efficacy, we analyzed immune parameters in peripheral 
blood, spleen and tumors in both pancreatic cancer and 
mesothelioma lysate- loaded DC therapy treated mice. 
In vaccinated mice, increased frequencies of circulating 
CD3+, CD4+ and CD8+T cells could be detected as early 
as 4 days after DC treatment (day −3 before tumor inoc-
ulation). These immune responses were durable and 
persisted over time until day of sacrifice (figure 1E). A 
more in- depth phenotypic analysis demonstrated that 
vaccinated mice had higher frequencies of activated 
(CD69+), proliferating (Ki-67+) and effector memory 
(CD44 +CD62L-) CD4+ and CD8+T cells in the peripheral 
blood compared with untreated mice. This did not differ 
between mesothelioma- lysate and pancreatic cancer- 
lysate DC- treated mice (figure 1F). In contrast to changes 
in T- cell frequencies, the expression of CD69+, Ki-67+ 
and CD44+CD62L- on circulating T cells of vaccinated 
mice waned over time (online supplementary figure S3). 
Higher frequencies of intratumoral CD4+ and CD8+T 
cells were noted, paralleling the delayed tumor growth 
observed after vaccination (figure 1G). CD8+ tumor infil-
trating lymphocytes (TILs) of treated mice more often 
expressed the memory marker CD44 and the proliferation 
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marker Ki-67, which was not observed in the spleen and 
peripheral blood at the time of sacrifice (figure 1H). 
This was also not observed for CD4 +TILs. Importantly, 
the frequencies of regulatory CD4 +CD25+FoxP3+TILs 
remained comparable between treated and untreated 
mice (figure 1G). Therefore, DC vaccination is able to 
induce the infiltration of PDAC tumors with activated, 
proliferating CD4+ and CD8+T cells without concomitant 
Treg- induction.
DC vaccination depends on tumor antigens and tumor-specific 
T cells
We then assessed whether T- cell responses induced by 
mesothelioma lysate- loaded DCs were reactive to tumor 
Figure 1 Mesothelioma lysate- DC vaccination is able to delay pancreatic tumor growth and induce strong T- cell immunity. 
(A) Dendritic cell (DC) vaccination study setup. (B) Expression of immunogenic tumor antigens as described by Cheever 
et al23 in the tumor cell line KPC3 and AE17. Percentages indicate amount of overlapping and non- overlapping genes. (C) 
Tumor volumes (with SEM) measured over time of untreated and treated mice. (D) Tumor size at the time of sacrifice (day 
20 after tumor injection). (E) Circulating CD4+ and CD8+T cell frequencies at day −3, 4 and 20. (F) Percentage of CD69+, 
Ki67+ and CD44+CD62L− subsets of CD4+ and CD8+ circulating T cells 4 days after DC vaccination. (G) CD3+, CD4+, CD8+ 
and CD4+CD25+FoxP3+TILs as a percentage of alive CD45 +cells at day 20 after tumor injection. (H) Expression of CD44 and 
Ki67 on CD4+ and CD8+T cells at day 20 in blood, spleen and tumor. n=8 per group. Significance was determined using the 
non- parametric Mann- Whitney U test. Data presented as the mean±SEM. *P<0.05,**P<0.01,***P<0.001.
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antigens present on pancreas carcinoma cells. Mice treated 
with mesothelioma lysate- loaded DCs had significantly 
smaller tumors compared with untreated mice or those 
treated with non- loaded DCs, suggesting that the delay 
in tumor outgrowth was due to a TAA- reactive immune 
response (figure 2A). Indeed, CD8 +T cells isolated 
from vaccinated mice responded in vitro specifically to 
autologous pancreatic cancer lysate- loaded DCs, while 
T cells from untreated mice or those from non- loaded 
DC vaccinated mice did not (figure 2B). On stimulation, 
higher frequencies of CD8 +T cells from mesothelioma 
lysate- loaded DC treated mice expressed CD107a (being 
a marker of cytotoxic degranulation), Granzyme B, 
interferon-γ (IFNγ) and tumor necrosis factor α (TNFα) 
compared with CD8 +T cells from untreated mice or 
mice treated with non- loaded DCs. This effect was not 
observed when CD8 +T cells were stimulated with DCs 
loaded with a control wild type tissue lysate (figure 2B), 
demonstrating that mesothelioma lysate- loaded DCs can 
generate tumor- antigen specific T cells reactive to anti-
gens also expressed by pancreatic cancer cells. In these 
in vitro assays, CD8 +T cells from vaccinated mice also 
responded better than those from untreated mice to DCs 
loaded with B16F10 melanoma lysate (online supple-
mentary figure S4), suggesting induction of immunity to 
shared tumor antigens across KPC3, AE17 and B16F10 as 
listed in online supplementary table S1.
CD40-agonistic antibody treatment sensitizes established 
pancreatic tumors to DC vaccination and improves efficacy
As DC therapy generated systemic antitumor immune 
responses capable of stalling tumor growth when given 
prophylactically, we set out to test its capacity to control 
established KPC3 tumors. Although our pilot study 
demonstrated that tumor lysate- loaded DCs are capable 
of inducing systemic changes in T- cell subsets, as a single 
therapy it was unable to increase intratumoral T cells or 
delay tumor growth (online supplementary figure S5). The 
lack of increased T- cell infiltration found in established 
tumors in the presence of a systemic immune response 
suggested that the PDAC TME might physically obstruct 
T cells from infiltrating the tumor. CD40- agonistic anti-
bodies have previously been found to allow T- cell infil-
tration due to TME- reorganization in pancreatic cancer, 
offering a treatment rationale for combination therapy 
with DC vaccination.16 As CD40 is also highly expressed 
on the tumor lysate- loaded DCs (online supplementary 
figure S2), administering the antibody early following 
DC transfer might offer additional synergy between these 
treatments (online supplementary figure S6a). Interest-
ingly, αCD40 combined with DC vaccination resulted in 
significant tumor growth control when compared with 
untreated mice while monotherapy DC or αCD40 did not 
(online supplementary figure S6b). αCD40 monotherapy 
was able to induce systemic and intratumoral responses 
(online supplementary figure S6c–f). To show that the 
efficacy of this combination therapy was not limited 
to pancreatic cancer or the C57BL/6 mouse strain, we 
performed a comparable experiment in a mesothelioma 
tumor model (CBA/J background) yielding similar 
results (online supplementary figure S7).
As treatment at day 5 after tumor cell injection still 
reflects minimal disease burden, we aimed at treating 
Figure 2 Tumor lysate DCs outperforms non- loaded DCs. (A) Tumor volume measured over time as individual tumor outgrowth 
curves and per group, and tumor size at day of sacrifice (day 21) of treated and untreated animals. (B) In vitro efficacy assay; 
relative production of CD107a, granzyme B, IFNγ and TNFα by CD8 +splenocytes of three treatment groups after stimulation 
with DCs loaded with autologous tumor lysate or control lung lysate, normalized for untreated mice. n=8 per group. Significance 
was determined using the non- parametric Mann- Whitney U test. Data presented as the mean±SEM. *P<0.05,**P<0.01. DC, 
dendritic cell; IFNγ, interferon-γ; TNFα, tumor necrosis factor α.
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larger tumors (day 10) using an intensified treatment 
schedule (figure 3A). In this experimental setup, tumor 
growth and survival of mice treated with monotherapy DC 
vaccination or αCD40 also did not significantly differ from 
untreated tumor- bearing mice (figure 3B–D and online 
supplementary figure S8). The combination therapy, 
however, significantly delayed tumor growth (figure 3B), 
led to significantly smaller tumor volumes and improved 
survival (figure 3C,D). In order to elucidate the immu-
nological prerequisites of therapeutic efficacy and to 
demonstrate if the observed antitumoral response is T- cell 
dependent, mice were depleted of CD4+ and CD8+T 
cells before receiving treatment (online supplementary 
figure S9). Antitumoral efficacy was retained in αCD4 
and isotype- treated mice receiving DC vaccination and 
αCD40 (figure 3E–G). However, therapeutic responses 
were mitigated in mice depleted for CD8 +T cells. Impor-
tantly, we assessed the efficacy of combination therapy in 
an orthotropic mouse model, in order to examine if our 
results could be replicated in a more translational model 
mimicking the anatomical location and phenotypic 
features of PDAC (figure 3H). Strikingly, 56% (5/9) of all 
combination therapy- treated mice were macroscopically 
free of tumor at the day of analysis (figure 3I and online 
supplementary figure S10). In contrast, all untreated or 
monotherapy- treated mice bore tumors and tumor sizes 
were significantly larger compared with the remaining 
combination therapy- treated mice with tumor (figure 3J).
Figure 3 DC vaccination-αCD40 combination therapy improves survival of tumor- bearing mice. (A) Subcutaneous tumor 
model study setup. Mice were treated with AE17- lysate DCs and FGK45. (B) Tumor volumes measured over time. (C) Tumor size 
at day 21. (D) Kaplan- Meier analysis of treated and untreated animals. (E) Tumor volumes measured over time. (F) Tumor size 
at day 22. (G) Kaplan- Meier analysis of treated and untreated animals. (H) Orthotopic tumor model study setup. (I) Percentage 
of tumor bearing mice. (J) Tumor weight on day 17. n=8–10 per group. Significance was determined using the non- parametric 
Mann- Whitney U test or log- rank test. Data presented as the mean±SEM. *P<0.05, **P<0.01, ***P<0.001. DC, dendritic cell.
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Interim peripheral blood analysis demonstrated that 
both monotherapy DC vaccination and αCD40 treatment 
induced higher frequencies of CD69+, Ki-67+ and PD-1 
+T cells. However, this effect was more confined to CD4 
+T cells when mice were only treated with DC vaccination, 
and to CD8 +T cells for monotherapy αCD40 (figure 4A). 
Combination therapy induced higher frequencies of 
CD69+, Ki-67+ and PD-1+ for both CD4+ and CD8+T 
cells. Enrichment over time of Ki-67+ and PD-1 +T cells 
was detected in mice treated with either combination 
therapy or αCD40 monotherapy. Furthermore, CD44 
+CD62L- effector memory T cells were significantly 
increased after both monotherapies and combination 
therapy (figure 4B). Over time, mice treated with combi-
nation therapy yielded the highest frequencies of effector 
memory T cells compared with mice treated with mono-
therapy or untreated mice. This was observed for both 
CD4+ and CD8+T cells. The enrichment of effector 
memory T- cell frequencies was less prominent after 
single DC vaccination and subsequent αCD40 treatment 
(online supplementary figure S6d), promoting the role 
of multiple vaccinations.
Combining DC vaccination and αCD40 remodels the TME, 
including T-cell exhaustion markers
To further assess the mechanistic underpinnings of 
combination immunotherapy, we performed extensive 
analysis on the tumor and intratumoral immune cells, 
both numerically and phenotypically, using gene expres-
sion analysis and multicolor flow cytometry. Intratumoral 
analysis revealed increased T- cell numbers in treated mice 
(figure 5A). No distinct changes in myeloid subsets could 
be found (online supplementary figure S11). However, 
DC therapy did induced a PD- L1 rich TME (figure 5B). 
To get a more profound insight in the intratumoral 
immune changes induced by combination therapy, we 
Figure 4 Immune activation in peripheral blood following AE17- lysate DC and FGK45 treatment. (A) Percentage of CD69+, 
Ki67+ and PD-1+ subsets of CD4+ and CD8+ circulating T cells at day 14 and 22. (B) Percentage of CD44 +CD62L− effector 
memory subsets and memory status of CD4+ and CD8+ circulating T cells at day 14 and day 22. n=8 per group. Significance 
was determined using the non- parametric Mann- Whitney U test. Data presented as the mean±SEM. *P<0.05, **P<0.01, 
***P<0.001. DC, dendritic cell.
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applied NanoString gene- expression technology on 
tumors of treated and untreated mice. Unsupervised 
clustering of significantly different immune- related 
genes revealed that tumors of untreated or monotherapy- 
treated mice displayed a distinct gene expression profile 
as compared with mice treated with the combination 
therapy (figure 5C,D and online supplementary figure 
S12), indicating a unique remodeling of the TME.
Mice treated with combination therapy had consistently 
lower transcript amounts of a wide range of inhibitory 
receptors, including Pdcd1 (PD-1), Ctla4, Entpd1 (CD39), 
Vsir (VISTA), Cd244 (2B4), Havcr2 (Tim-3) and Tigit, 
compared with monotherapy- treated mice (figure 6A). 
Remarkably, both monotherapies induced higher expres-
sion of various effector molecules like Prf1 (perforin), 
Gzma and Gzmb (Granzymes) and Ifng. Differential gene 
expression analysis between monotherapy groups and 
the combination therapy confirmed significantly higher 
transcript levels of both inhibitory receptors and effector 
molecules in tumors of monotherapy- treated mice 
(online supplementary figure S13).
Although the findings of increased effector molecules 
in the absence of clinical benefit may seem counterintu-
itive, similar cells displaying high levels of coinhibitory 
and effector molecules were recently found to be consis-
tent with a terminally exhausted T- cell phenotype.24–28 
In line with these findings, gene- set enrichment analysis 
(GSEA) revealed that gene transcripts associated with 
T- cell exhaustion were significantly enriched in tumors of 
αCD40 therapy treated mice compared with combination 
therapy treated animals (online supplementary figure 
S14a). This was not observed for DC therapy- treated 
mice. As increased levels of coinhibitory receptors and 
effector molecules may be linked to a more exhausted 
T- cell phenotype, we interrogated markers associated 
with this state. High expression of Tbx21 (T- Bet) and 
Klrg1 was found in both monotherapies while high expres-
sion of the transcription factor Eomes was only found in 
Figure 5 Tumors of combination therapy- treated mice displayed a distinct gene expression profile compared with tumors 
of untreated or monotherapy- treated mice (A) number of CD3+, CD4+, CD8+, CD19+ and CD335+TILs per Mg tumor at 
end- stage disease. (B) PD- L1 MFI of non- myeloid (CD45-), monocyte (CD45 +F4/80- CD11b+Ly6C+Ly6G-), granulocyte 
(CD45 +F4/80- CD11b+Ly6C- Ly6G+), cdc1 (CD45 +F4/80- CD11b+CD11b- CD11c+MHCII+ CD103+), cdc2 (CD45 +F4/80- 
CD11b+CD11c+MHCII+), MDSC (CD45 +F4/80- CD11b+Ly6CintLy6Gint) and TAM (CD45 +F4/80+CD11b+) population, and 
percentage of PD- L1+ subset of cDC2s, MDSCs and TAMs. (C) Unsupervised clustering of genes significantly different between 
groups. Downregulated genes are marked blue and upregulated genes are marked yellow. (D) t- SNE clustering of individual 
tumor samples based on genes significant different between groups. n=5–10 per group. Significance was determined using the 
non- parametric Mann- Whitney U test. Data presented as the mean±SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. DC, 
dendritic cell; MDSCs, myeloid derived suppressor cells; TAMs, tumor- associated macrophages.
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aCD40 treated mice (figure 6A). Interestingly, combi-
nation therapy induced higher expression of Sell (L- se-
lectin) and the chemokine receptor Cxcr5 in the tumor 
compared with other groups. Furthermore, we also found 
lower expression of genes related to various collagen 
markers and ‘M2’ phenotype macrophages after αCD40 
therapy indicating TME remodeling. In order to confirm 
αCD40- induced stromalysis, histochemical staining were 
performed. Tumors of both αCD40 monotherapy as 
combination therapy- treated mice showed decreased 
collagen content (online supplementary figure S15). Strik-
ingly, high mRNA expression of genes related to glycol-
ysis were detected in tumors after combination therapy 
as compared with αCD40 monotherapy (figure 6A). A 
glycolysis GSEA indeed revealed higher activity in the 
combination therapy treated mice compared with αCD40 
treated mice (online supplementary figure S14b). Combi-
nation therapy was also able to significantly upregulate 
expression of Vegfa, adm and Flt1 compared with αCD40 
treated mice (online supplementary figure S13). This is 
indicative for angiogenesis and vascular formation and 
may promote immune cell infiltration into the tumor. 
When immunohistochemically stained for the endothe-
lial marker CD31, tumors of combination therapy- treated 
mice did express more CD31 compared with untreated or 
monotherapy- treated mice (online supplementary figure 
S16).
As gene expression analysis was performed on whole 
tumor material, inhibitory markers and effector mole-
cules were further validated and quantified at the 
protein level on both CD4+ and CD8+TILs (figure 6B,C 
and online supplementary figure S17). Untreated and 
αCD40 treated mice had the highest frequencies of CD8 
+TILs expressing various inhibitory receptors (ie, PD-1, 
Tim-3, VISTA, CD39, NKG2A) (figure 6B). However, only 
αCD40 treated mice had the highest number of CD8 
+TILs expressing coinhibitory receptors. DC therapy was 
able to reduce the frequencies of PD-1+, Tim-3+, VISTA+, 
CD39 +TILs. A similar trend was also observed when 
Figure 6 DC vaccination is able to reduce hallmarks of T- cell exhaustion. (A) Heatmap illustrating the average transcript 
expression of the indicated genes, grouped by function. Rows represent averaged z- scores. (B) Number and percentage of 
PD-1+, Tim-3+, VISTA+, CD39+ and NKG2A+ subsets of CD8 +TILs. (C) Number and percentage of IFNγ+, granzyme B+, IL-
10+ and Ki67+ subsets of CD8 +TILs. n=7–8 per group. Significance was determined using the non- parametric Mann- Whitney 
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coexpression of multiple inhibitory receptors was assessed 
(online supplementary figure S17c‒d). In addition, DC 
vaccinated and combination therapy treated mice had 
the highest frequencies of PD-1/Tim-3 double negative 
TIL, which have been described to exhibit the highest 
effector potential, whereas PD-1/TIM-3 double positive 
T cells are known to be severely dysfunctional.26 αCD40 
mediated induction of IFNγ+ and granzyme B+TILs came 
at the expense of increased numbers of cells producing 
interleukin-10 (IL-10) (figure 6C). Both the mRNA and 
protein- expression data point to a preferential induction 
of effector T- cells expressing less multiple coinhibitory 
receptors in the combination immunotherapy treated, 
as compared with CD40- agonistic monotherapy- treated 
mice.
Recently, targeting NKG2A on T cells has been 
described as a novel approach to promote antitumor 
immunity and has been linked to T- cell dysfunction.29 30 
Interestingly, αCD40 induced the highest numbers of 
NKG2A+CD8+TILs compared with combination therapy 
arm (figure 6B). Moreover, although αCD40 therapy 
increased TIL numbers, the frequencies of prolifer-
ating TILs were lower compared with untreated mice 
suggesting that this is not explained by local expansion, 
but enhanced infiltration (figure 6C). Altogether, these 
findings offer an explanation for the observed efficacy 
of DC- CD40- agonist combination therapy where an 
influx of T cells exhibiting low levels of co- inhibitory 
checkpoints is associated with restricted tumor growth.
DISCUSSION
Our data highlight that rationally combining immuno-
therapies in pancreatic cancer can lead to synergistic 
improvements in antitumor T- cell immunity and clinical 
responses. For these studies, we used immune- competent 
mice- bearing PDAC tumors obtained from KrasG12D/+;Tr-
p53R172H/+;Pdx-1- Cre (KPC) mice. This model mimics 
(immune) phenotypic features and the aggressiveness 
of human pancreatic adenocarcinoma.16 31 We mainly 
focused on DC- based therapy to strengthen the tumor- 
specific effector T- cell response. Previous trials in pancre-
atic cancer patients used single peptide or autologous 
tumor as a lysate source for DC therapy. We assessed 
the possibility of loading DCs with mesothelioma lysate 
based on the rationale that cross- reactive T cells would 
be generated due to expression of a number of shared 
TAAs by both mesothelioma and pancreatic cancer. The 
use of an allogeneic- tumor lysate offers an off- the- shelf 
approach which is not dependent on the identification of 
immunodominant epitopes and can be used irrespective 
of the patient’s HLA type and exploits a broad spectrum 
of TAAs.32 We found that mesothelioma- lysate DC therapy 
was able to delay pancreatic tumor growth, generate 
KPC- reactive T cells and induce TIL influx, confirming 
cross- reactivity. Although some efficacy was observed with 
non- loaded DCs, possibly by an unspecific inflammatory 
response that activates bystander T cells or during culture 
phagocytosed bovine serum proteins, the use of tumor 
lysate- loaded DCs had significant higher efficacy against 
the tumor in vivo and in vitro (figure 2). Interestingly, 
cross- reactivity could also be found in vitro when B16F10 
lysate was used to load DCs but not to non- loaded DCs 
(online supplementary figure S4), indicating the involve-
ment of shared antigens (online supplementary table S1).
We also investigated if targeting CD40 is able to control 
tumor growth in established disease. CD40 can be found 
on B cells, DCs and macrophages and ligation leads to 
activation.33 αCD40 therapy may, therefore, also acti-
vate endogenous DCs that present tumor antigens and 
contribute to a monotherapy effect. Also, Schoenberger 
and Bennett et al demonstrated that CD40- activated 
APCs might replace the requirement for CD4 +T helper- 
mediated licensing, thereby lowering the threshold for 
CD8 +effector T- cell priming. This could explain why CD4 
+T cell depletion prior combination immunotherapy 
did not affect efficacy.34 35 Alternatively, CD40 ligation 
may also license delivered DCs, thereby enhancing their 
capacity to prime CD8 +T cells.36 37 Indeed, when bone 
marrow- derived DCs were treated with αCD40, increased 
IL-12 production could be detected (online supplemen-
tary figure S18). Furthermore, αCD40 therapy can also 
directly modulate the TME: targeting CD40 on macro-
phages can lead to phenotypic polarization from immu-
nosuppressive ‘M2’ into inflammatory ‘M1’ macrophages, 
the latter being tumoricidal and capable of ablating 
tumor stroma.16 38 In line with this thought, our mRNA 
expression data and histochemical staining on tumors 
confirmed decreased collagen content after αCD40 mono 
and combination therapy (figure 6A). Also, lower expres-
sion of mRNA levels related to M2 macrophages was 
found in tumors of mice treated with αCD40 (figure 6A). 
Furthermore, it was shown that M2 macrophage- derived 
granulin contributes to CD8 +T cell exclusion and that 
this process is driven by colony- stimulating factor-1 
(CSF-1). It has been found that CSF-1 inhibition leads to 
desmoplasia depletion and sensitizes pancreatic cancer 
to immune checkpoint blockade therapy.39 We were able 
to show lower Csf1 mRNA levels in tumors after αCD40 
therapy and combination therapy (figure 6A). A recently 
reported combination therapy involving αCD40 and 
αPD-1 therapy showed promising results in preclinical 
PDAC models, and demonstrated that therapy repro-
grams the TME resulting in the increase of DCs and 
decrease of granulocytic- MDSCs.40 As we now focused 
on the T- cell phenotype responsible for slowing tumor 
progression following combination treatment, further 
in- depth studies immediately following αCD40 therapy 
are likely required to formally dissect its spatiotemporal 
roles on macrophages and DCs in promoting antitumor 
immune responses.
Interestingly, despite the absence of clinical responses 
in monotherapy- treated animals in the established tumor 
model, both monotherapy and combination therapy- 
treated mice were able to increase total CD3 +TIL 
numbers. The effect of DC therapy was most pronounced 
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on CD4 +T cells and less on CD8 +T cells whereas αCD40 
treatment displayed an inverse pattern. DC and αCD40 
treated mice showed improved survival and increased 
both CD4+ and CD8+ intratumoral T- cell numbers. 
However, we demonstrated that the clinical response 
was primarily driven by CD8 +T cells (figure 3E–G). The 
sensitizing role of DC vaccination may be mainly priming 
of MHC class I- restricted cytotoxic T lymphocytes. Even 
though CD40 agonistic antibodies significantly increased 
T- cell infiltration in established pancreatic tumors, clin-
ical efficacy was lacking, prompting further phenotypic 
analysis of these cells. We observed high expression 
of various inhibitory receptors and effector molecules 
on TILs of αCD40 monotherapy- treated mice when 
compared with the other treatment groups. Studies only 
recently published have associated this phenotype with 
that of terminally exhausted T cells in both solid cancer 
and chronic viral infection settings.25 41 Although our 
mRNA expression data also demonstrated the expres-
sion of various inhibitory receptors in DC monotherapy- 
treated mice, mRNA analysis was performed on whole 
tumor tissue, challenging the interpretation of our data as 
we were not able to assign specific markers to individual 
immune cell subsets. However, lower amounts of mRNA 
of various stimulatory receptors (ie, CD28, ICOS, GITR, 
CD137, OX-40) and high expression of Tbx21 (T- Bet) and 
Eomes found in αCD40 monotherapy- treated mice suggest 
that this phenotype is primarily restricted to these tumors. 
In addition, KLRG1hiIL7rlo CD8 +T cells have previously 
been described as dysfunctional.42 We found that mono-
therapy with αCD40 induced higher expression of Klrg1 
but not Il7r, whereas DC vaccination increased the levels 
of both Klrg1 and Il7r. In accordance with the aforemen-
tioned phenotype, Sell (L- selectin), a marker associated 
with naïve- like memory T- cells and T- cell homing, was 
particularly induced in mice treated with combination 
therapy.24 25 28 Finally, the chemokine receptor CXCR5 
has been recently found to mark a specific T- cell popula-
tion capable of responding to PD-1 checkpoint blocking 
antibodies, which expresses lower levels of coinhibitory 
receptors and effector molecules as compared with 
their CXCR5- negative counterparts.25 26 41 We found that 
combination DC and αCD40 therapy indeed induced 
higher Cxcr5 expression in the tumor compared with 
other groups.
Flow cytometry analysis confirmed the reduced expres-
sion of various inhibitory markers on CD8 +TILs derived 
from combination therapy- treated mice compared with 
αCD40- treated mice. In addition, the lower prolifer-
ation rate as evidenced by ex vivo measurements of 
Ki-67 in combination therapy treated animals also 
matches with an improved T- cell phenotype, as others 
have previously found these cells to persist in culture 
longer compared with their Ki-67- high counterparts.25 
As human cancers grow at a considerably slower pace 
than most murine tumor models, it is conceivable that 
longer T- cell persistence is crucial for durable tumor 
control.
The presence of low amounts of glycolysis- related 
gene transcripts following αCD40 monotherapy fits 
with a more exhausted, terminally differentiated 
memory T- cell state, as has been proposed by others.43 44 
Glut-1 (Slc2a1) was found to be essential for T- cell acti-
vation and Slc2a1 was highly expressed in combination 
therapy treated mice.45 However, as gene expression 
was performed on whole tumor material, it is unclear 
whether glycolysis- related transcripts originated from 
tumor cells or immune infiltrates. Further functional 
studies on our combination treated T- cell phenotype 
are needed to truly assess which factors determine their 
superior antitumor efficacy.
DCs loaded with allogeneic mesothelioma- tumor 
cell lysate have already proven to be feasible, with clin-
ical efficacy in the absence of toxicity in patients with 
mesothelioma.22 Following this, a phase II clinical trial 
examining whether this holds true for macroscopically 
disease- free, postresection PDAC patients is currently 
being conducted (REACtiVe Trial; Netherlands Trial 
Register NL7432). However, as the majority of pancre-
atic patients presents with irresectable or metastatic 
disease, rational and safe treatment combinations are 
needed to offer perspective for this group of patients 
too. Currently, several studies with combination strate-
gies incorporating CD40 agonists in PDAC patients are 
ongoing and recruiting (NCT03214250; NCT02588443; 
NCT03329950). We have shown that DC- therapy 
pretreatment allows for proper CD40- agonist efficacy 
by precluding the formation of T- cells associated with 
an exhaustion phenotype when administered alone. 
The lack of DC- therapy toxicity in patients is of partic-
ular importance since CD40- agonistic antibodies are 
associated with serious adverse events leading to prema-
ture termination of treatment in some patients.16 46 
To assess the feasibility and safety of our combinatory 
approach we are currently in the process of initiating a 
trial involving DC- CD40- agonist combination therapy in 
metastatic disease. Since DC vaccination also induced 
a PD- L1 rich TME, future combination strategies with 
immune checkpoint blockers are warranted.
In conclusion, we have found pancreatic cancer 
and mesothelioma lysate- loaded DCs to be effective in 
restraining immunologically cold pancreatic tumors 
when administered prophylactically. In established 
tumors, effective intratumoral immunity was achieved 
when DC vaccination was combined with CD40- agonistic 
antibodies, generating non- redundant immunological 
effects capable of restraining tumor progression.
METHODS
Mice
C57BL/6 and CBA/J mice were purchased from 
Charles River Laboratories and Janvier, respectively. 
All mice were housed in individually ventilated cages, 
maintained under specific pathogen- free conditions 
and used at 8–10 weeks of age. All mouse experiments 
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were controlled by the animal welfare committee (IvD) 
of the Leiden University Medical Center (Leiden) 
or Erasmus University Medical Center (Rotterdam) 
and approved by the national central committee of 
animal experiments (CCD) under the permit numbers 
AVD116002015271 and AVD101002017867, in accor-
dance with the Dutch Act on Animal Experimentation 
and European Union (EU) Directive 2010/63/EU.
Mouse tumor cell lines
The pancreatic cancer KPC3 cell line is derived from 
a primary tumor of a female KPC mouse.31 AE17 and 
AC29 cell lines are derived from mesothelioma tumors 
in C57BL/6 and CBA/J mice and kindly provided by 
Bruce W.S. Robinson (Queen Elizabeth II Medical 
Center, Nedlands, Australia) and Peter D. Katsikis 
(Erasmus Medical Center, Rotterdam, The Nether-
lands), respectively. KPC3, AE17 and AC29 tumor cell 
lines were cultured in RPMI 1640 containing glutamax- I 
(Gibco), 50 µg/mL gentamicin (Invitrogen), and 8% 
fetal bovine serum (FBS) (Gibco) at 37°C in a humid-
ified atmosphere containing 5% CO2. Cell lines were 
assured to be free of rodent viruses and Mycoplasma 
by regular PCR analysis. Low passage number cultures 
from stock vials were used for all experiments. Transcrip-
tomes of KPC3, AE17 and B16F10 cells from stock vials 
were analyzed by Macrogen NGS Services (Macrogen, 
Seoul, Republic of Korea). Illumina platform was used 
with TruSeq Stranded Total RNA LT Sample Prep Kit 
(Human Mouse Rat) Library. MC38 transcriptome 
data were previously published47 and downloaded from 
Sequence Read Archive SRX6812144.
Generation of DC vaccination
Bone marrow- derived cells seeded in 100 mm Petri 
dishes (day 0) and cultured in 10 mL DC culture 
medium: RPMI 1640 containing glutamax- I (Gibco), 
50 µg/mL gentamicin (Invitrogen), 5% FBS (Gibco), 
50 mol/L mercaptoethanol (Sigma- Aldrich) and 20 ng/
mL recombinant murine granulocyte macrophage- CSF 
(kindly provided by B. Lambrecht, VIB Ghent, 
Belgium). Cells were cultured at 37°C in a humidified 
atmosphere containing 5% CO2. At day 3 and 6, fresh 
DC culture medium was added. Tumor cell lysate was 
prepared by freeze- thawing and subsequent sonication 
for 3×10 s with an amplitude of 10 mm, using a Soniprep 
150 ultrasonic disintegrator equipped with a microtip 
(Sanyo Gallenkamp). After 9 days of culture, tumor cell 
lysate was added to the DC cultures, to the equivalent of 
three tumor cells per DC. After 8 hours, 10 g/mL CpG 
(ISS- ODN 1668, Invitrogen) was added to the culture 
to allow complete maturation while incubated over-
night. The next day, DCs were harvested and washed 
three times in PBS. The quality of the DC preparation 
was determined by cell counting, morphology and cell 
surface marker expression by flow cytometry, as previ-
ously described.48
In vivo experiments
Cultured tumor cells were harvested at 70% conflu-
ency. The pancreatic cancer model was generated by 
injecting 100 000 KPC3 cells in 100 ul PBS/0.1% BSA 
subcutaneously in the flank of the mice or by injecting 
10 000 KPC3 cells in 20 ul PBS/0.1% BSA orthotopically 
in the pancreas. The mesothelioma model was gener-
ated by injecting 20×106 AC29 cells in 200 µL PBS intra-
peritoneally. Subcutaneous tumors were measured 3–7 
times a week in three dimensions using a caliper. Mice 
were treated with DC immunotherapy at day −7 (7 days 
before tumor injection) or day 5. Repeated DC vaccina-
tion occurred at day 10, 14 and 18 in mice with subcuta-
neous pancreatic tumors and at day 3, 7 and 11 in mice 
with orthotopic pancreatic tumors. One day after DC 
vaccination, FGK45 or isotype IgG2a was administered 
intraperitoneally (BioXCell, 70 µg/dose). Mice with 
AC29 tumors were DC vaccinated on day 10 followed by 
FGK45 on day 10, 12 and 14. For CD4+ and CD8+T cell 
depletion, mice were injected i.p. 2 days before treat-
ment and every 6 days onward with GK1.5 and/or 2.42 
or isotype IgG2b (BioXCell, 100 µg/dose). Peripheral 
blood samples for interim analysis were collected 4 days 
after DC vaccination and were immediately stained (see 
the flow cytometry section). Mice were sacrificed at the 
predefined experimental endpoint (figures 1–3H–J) or 
when tumors reached a volume of 1000 or 1500 mm3.
Cell preparation and flow cytometry
Whole blood or single- cell suspensions of spleen and 
tumor were prepared for flow cytometry. Spleens 
were passed through a 100 µm mesh with RPMI 1640 
containing glutamax- I (Gibco) and collected through 
centrifugation. Lymph nodes were excluded during 
tumor collection and tumors were dissociated using a 
validated tumor dissociation system (Miltenyi Biotec). 
To assess cytokine production, lymphoid cells were 
stimulated for 4 hours at 37°C using PMA and iono-
mycin supplemented with GolgiStop (BD Biosciences). 
Intracellular cytokine and transcription factor staining 
was performed using PFA/Saponin protocol and Foxp3 
Transcription Factor Staining Buffer Kit (eBioscience), 
respectively. Cell surface staining was performed after 
blocking Fc II/III receptor using antimouse 2.4G2 anti-
body (kindly provided by L. Boon, Bioceros, Utrecht, 
the Netherlands) by incubating cells with fluores-
cently conjugated mAbs directed against murine CD3e 
(145–2 C11), CD4 (GK1.5), CD8a (53-67), CD11b 
(M1/70), CD11c (N418), CD19 (1D3), CD25 (PC61), 
CD40 (1C10), CD44 (IM7), CD45 (30- F11), CD62L 
(MEL-14), CD69 (H1.2F3), CD80 (16- 20A2), CD86 
(GL1), CD103 (2E7), CD107a (1D4B), CD335 (29A1.4), 
F4/80 (BM8), FoxP3 (FJK- 16s), Granzyme B (NGZB), 
IFNγ (XMG1.2), IL-2 (JES6- 5H4), IL-10 (JES5- 16E3), 
Ki-67 (SolA15), LAG-3 (eBioC9B7W), Ly6C (AL-21), 
Ly6G (RB6.8C5), MHCII (M5/114.15.2), NKG2A 
(16a11), PD1 (J43) PDL1 (MIH5), TIM3 (8B.2C12), 
TNFα (MP6- XT22), VISTA (MH5A). Cells were in 
P
rotected by copyright.















12 Lau SP, et al. J Immunother Cancer 2020;8:e000772. doi:10.1136/jitc-2020-000772
Open access 
addition stained for viability using fixable LIVE/DEAD 
aqua cell stain (Thermo Fisher Scientific). Data were 
acquired using an LSR- II flow cytometer (BD Biosci-
ences) and analyzed by FlowJo v10.0.7 (Treestar).
In vitro experiments
Tumor antigen- specific T- cell detection assay: Dissected 
subcutaneous tumors from treated mice and lungs from 
wild- type C57BL/6 mice were beads homogenized in 
150 µL Milli- Q for four cycles of 1 min. A Bradford assay 
was performed in order to assess the protein concen-
tration. Bone marrow- derived DCs were generated as 
described above, and loaded with 70 µg tumor lysate or 
200 µg lung lysate/mL DC suspension. Tumor cell line 
lysate loaded DCs were prepared as described above. 
Tumor loaded DCs were in in vitro cocultured with paired 
splenocytes at a ratio of 1:10 for 4 hours at 37°C supple-
mented with GolgiStop (BD Biosciences). After 4 hours, 
intracellular cytokine expression was assessed by flow 
cytometry as described above.
IL- 12p40 detection: Bone marrow- derived DCs were 
cultured as described above. At day 9, FGK45 (BioXCell, 
30 µg/mL) or isotype IgG2b (BioXCell, 30 µg/mL) was 
added to the DC culture. After 24 hours, supernatant was 
collected and a sandwich ELISA assay was performed as 
previously described.37
(Immuno)histochemistry
Immunohistochemistry was performed with an auto-
mated, validated and accredited staining system 
(Ventana Benchmark Discovery ULTRA, Ventana 
Medical Systems, USA) using Omnimap antirabbit or 
mouse and the universal DAB detection Kit. In brief, 
following deparaffinization and heat- induced antigen 
retrieval the tissue samples were incubated according 
to their optimized time with CD31 (Abcam; polyclonal). 
Incubation was followed by hematoxylin II counter stain 
for 8 min and then a blue coloring reagent for 8 min 
according to the manufactures instructions. Tonsil 
tissue was used as positive control. Thrichome blue was 
stained using optimized protocol provided in the fully 
automated Ventana Benchmark Special staines system. 
Sirius Red was stained by hand, in brief, following depa-
raffinization slides were rehydrated by passage through 
decreasing ethanol series, 5 min predifferentation step 
using 0.2% fosformolybdeen- acid followed by 45 min 
incubation with 0.1% Sirius Red solution. Slides were 
analyzed using polarization method.
mRNA expression analysis
NanoString nCounter Technologies was applied on 
120 µm of Tissue- Tek(Sakura)- embedded fresh frozen 
tumor samples using the PanCancer IO 360 Panel. To 
identify the differentially expressed genes, raw data 
was normalized using the values of the most stable 15 
housekeeping genes selected by applying the geNorm 
algorithm. Unsupervised clustering of normalized gene 
expression values (row Z- scores) was performed using 
the complete linkage method with Euclidean distance 
measure or standard Principal Component Analysis 
(PCA)/T- distributed Stochastic Neighbor Embedding 
(t- SNE) functions in R (through RStudio V.1.1.463). For 
the volcano plots, Mann- Whitney U test was conducted 
to compare the normalized count values in two groups 
(ie, monotherapy vs combination therapy) for each of 
the 750 markers. The original p values were adjusted 
for multiple testing using Benjamini- Hochberg proce-
dure. All calculation and the volcano plots were done 
in program R.
GSEA was performed by ranking all genes based on 
difference of means scaled by the standard deviation 
(signal- to- noise).49 Previously reported gene sets M9480 
and M5937 were used for exhausted phenotype and 
glycolysis enrichment analysis,50 respectively. The false- 
discovery rate adjusted p values (q- value) was considered 
significant when <0.05.
Statistical analysis
Difference between groups of interest were statisti-
cally analyzed with the non- parametric Mann- Whitney 
U test. Data are displayed as means with the SE of 
the mean and analyzed using GraphPad Prism soft-
ware (Graphpad, V.7.0a). Survival data were plotted 
as Kaplan- Meier survival curves. The non- parametric 
log- rank test (Mantel- Cox test) was used to compare 
the survival distribution of groups of mice. In all cases 
a p value of 0.05 and below was considered significant 
(*), p<0.01(**), p<0.001 (***) and p<0.0001 (****) as 
highly significant.
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